• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rethinking surrogate endpoints in metastatic colorectal cancer: counting chickens only when they hatch.

作者信息

Ruffolo Luis I, D'Angelica Michael

机构信息

Department of Surgery, Hepatopancreatobiliary Service, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.

Weill Cornell Medical College, Cornell University, New York City, NY, USA.

出版信息

J Gastrointest Oncol. 2025 Aug 30;16(4):1763-1767. doi: 10.21037/jgo-2025-386. Epub 2025 Aug 25.

DOI:10.21037/jgo-2025-386
PMID:40950350
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12432952/
Abstract
摘要

相似文献

1
Rethinking surrogate endpoints in metastatic colorectal cancer: counting chickens only when they hatch.重新审视转移性结直肠癌的替代终点：蛋未孵化，勿数小鸡。
J Gastrointest Oncol. 2025 Aug 30;16(4):1763-1767. doi: 10.21037/jgo-2025-386. Epub 2025 Aug 25.
2
Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease.肝外疾病患者行结直肠肝转移灶切除术的结局的系统评价。
Eur J Cancer. 2014 Jul;50(10):1747-1757. doi: 10.1016/j.ejca.2014.03.277. Epub 2014 Apr 21.
3
Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: Systematic review of all literature and meta-analysis of observational studies.细胞减灭术和腹腔热灌注化疗联合结直肠癌肝转移灶治愈性治疗的腹膜转移：所有文献的系统评价和观察性研究的荟萃分析。
Cancer Treat Rev. 2013 Jun;39(4):321-7. doi: 10.1016/j.ctrv.2012.11.003. Epub 2012 Dec 12.
4
Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy - a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol.肝动脉灌注化疗强化治疗系统诱导化疗后仍不可切除的肝单发结直肠癌转移患者 - 一项随机 II 期研究--SULTAN UCGI 30/PRODIGE 53（NCT03164655）-研究方案。
BMC Cancer. 2020 Jan 30;20(1):74. doi: 10.1186/s12885-020-6571-7.
5
Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC).结直肠癌肝转移灶切除术后使用替西莫肽进行辅助性MUC疫苗接种：一项随机、双盲、安慰剂对照、多中心AIO II期试验（LICC）
Oncoimmunology. 2020 Aug 23;9(1):1806680. doi: 10.1080/2162402X.2020.1806680.
6
A systematic review of hepatic artery chemotherapy after hepatic resection of colorectal cancer metastatic to the liver.结直肠癌肝转移肝切除术后肝动脉化疗的系统评价
Dis Colon Rectum. 2004 May;47(5):739-45. doi: 10.1007/s10350-003-0113-7. Epub 2004 Mar 25.
7
"Two-stage resection of synchronous liver metastases in colorectal cancer leads to a survival benefit: a retrospective comparative cohort study".结直肠癌同步肝转移的两阶段切除术可带来生存获益：一项回顾性比较队列研究
Langenbecks Arch Surg. 2025 Aug 28;410(1):253. doi: 10.1007/s00423-025-03840-3.
8
Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.KRAS 和 BRAF 基因突变对肝切除术后转移性结直肠癌患者生存的影响：系统评价和荟萃分析。
Clin Colorectal Cancer. 2017 Sep;16(3):e153-e163. doi: 10.1016/j.clcc.2017.01.004. Epub 2017 Jan 25.
9
Perioperative Chemotherapy is Associated with Superior Overall Survival in Patients with Synchronous Colorectal Liver Metastases.围手术期化疗与同步结直肠癌肝转移患者的总生存时间改善相关。
Ann Surg Oncol. 2023 Dec;30(13):7986-7995. doi: 10.1245/s10434-023-14302-9. Epub 2023 Sep 29.
10
Transarterial (chemo)embolisation versus systemic chemotherapy for colorectal cancer liver metastases.经动脉（化疗）栓塞与全身化疗治疗结直肠癌肝转移。
Cochrane Database Syst Rev. 2024 Aug 9;8(8):CD012757. doi: 10.1002/14651858.CD012757.pub2.

本文引用的文献

1
Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial.小尺寸结直肠癌肝转移灶的热消融与手术切除对比研究（COLLISION）：一项国际、随机、对照、3期非劣效性试验
Lancet Oncol. 2025 Feb;26(2):187-199. doi: 10.1016/S1470-2045(24)00660-0. Epub 2025 Jan 20.
2
First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases: Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial.初治不可切除结直肠癌肝转移的一线全身治疗：CAIRO5随机临床试验的事后分析
JAMA Oncol. 2025 Jan 1;11(1):36-45. doi: 10.1001/jamaoncol.2024.5174.
3
Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial.
肝移植联合化疗与单纯化疗治疗无法根治性切除的结直肠癌肝转移患者（TransMet）：一项多中心、开放标签、前瞻性、随机对照临床试验的结果。
Lancet. 2024 Sep 21;404(10458):1107-1118. doi: 10.1016/S0140-6736(24)01595-2.
4
First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.初治不可切除的结直肠癌肝转移患者的一线全身治疗策略（CAIRO5）：一项来自荷兰结直肠癌研究组的开放标签、多中心、随机、对照3期研究
Lancet Oncol. 2023 Jul;24(7):757-771. doi: 10.1016/S1470-2045(23)00219-X. Epub 2023 Jun 14.
5
Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis.无复发生存与总生存作为结直肠癌肝转移切除术后研究的主要终点：一项回顾性研究和荟萃分析。
Lancet Oncol. 2022 Oct;23(10):1332-1342. doi: 10.1016/S1470-2045(22)00506-X. Epub 2022 Sep 1.
6
Recipient and Donor Outcomes After Living-Donor Liver Transplant for Unresectable Colorectal Liver Metastases.不可切除结直肠癌肝转移患者接受活体肝移植后的受体和供体结局。
JAMA Surg. 2022 Jun 1;157(6):524-530. doi: 10.1001/jamasurg.2022.0300.
7
Hepatectomy Followed by mFOLFOX6 Versus Hepatectomy Alone for Liver-Only Metastatic Colorectal Cancer (JCOG0603): A Phase II or III Randomized Controlled Trial.mFOLFOX6方案辅助肝切除与单纯肝切除治疗单纯肝转移结直肠癌的比较（JCOG0603）：一项II期或III期随机对照试验
J Clin Oncol. 2021 Dec 1;39(34):3789-3799. doi: 10.1200/JCO.21.01032. Epub 2021 Sep 14.
8
Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.KRAS、BRAF、PI3K和TP53基因突变分析对可切除和不可切除结直肠癌肝转移的临床意义及预后相关性：当前证据的系统评价
Surg Oncol. 2018 Jun;27(2):280-288. doi: 10.1016/j.suronc.2018.05.012. Epub 2018 May 8.
9
Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases.结直肠癌肝转移中 RAS 和进化高风险 TP53 双突变的有害影响。
Ann Surg. 2019 May;269(5):917-923. doi: 10.1097/SLA.0000000000002450.
10
The Tumor Burden Score: A New "Metro-ticket" Prognostic Tool For Colorectal Liver Metastases Based on Tumor Size and Number of Tumors.肿瘤负荷评分：一种基于肿瘤大小和肿瘤数量的用于结直肠癌肝转移的新型“地铁票”预后工具。
Ann Surg. 2018 Jan;267(1):132-141. doi: 10.1097/SLA.0000000000002064.